AIT THERAPEUTIC Revenue, Profits - AITB Quarterly Income Statement

Add to My Stocks
$4.32 $0.04 (0.93%) AITB stock closing price Sep 21, 2018 (Closing)

Financial analysis of AIT THERAPEUTIC involves more than just checking the AIT THERAPEUTIC stock price, by looking at the financial statements of the company in detail. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the AITB stock is bound to reflect the impact of the QOQ decline of 0. Revenue for year 2019 Q1 is $- and has decreased from $- quarter on quarter as is evident when you compare the latest figures in the latest AIT THERAPEUTIC profit and loss statement with those of the prior corresponding period. Also see AIT THERAPEUTIC assets and AIT THERAPEUTIC free cash flow for a complete valuation of AITB stock.

View and download details of revenue and profits for AIT THERAPEUTIC for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Apr - Mar2019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q4
AIT THERAPEUTIC Revenues or Net Sales
----------
Cost Of Goods Sold (COGS)----------
AIT THERAPEUTIC Gross Profit
----------
Research & Development Expense1.06M-1.22M1.19M-1.43M----
Selling General & Admin Expense--1.17M-2.47M2.12M----
Income Before Depreciation Depletion Amortization-1.76M--2.39M-2.05M-3.06M-3.56M-0.63M-0.16M-0.62M-0.92M
Depreciation Depletion Amortization----------
Non Operating Income----------
Interest Expense1.25M--0.65M5.09M-0.18M2.71M----
AIT THERAPEUTIC Pretax Income
-3M--1.75M-7.14M-2.88M-6.27M-1M-0.48M-0.95M-1.26M
Provision for Income Taxes---0.01M----0.01M---
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-3M1.05M-1.73M-7.15M-2.88M-6.28M-0.98M-0.5M-0.97M-1.27M
Extraordinary Items & Discontinued Operations----------
AIT THERAPEUTIC Profit/ Loss (Net Income)
-3M1.05M-1.73M-7.15M-2.88M-6.28M-0.98M-0.5M-0.97M-1.27M
Average Shares used to compute Diluted EPS8.4M7.25M6.19M6.05M6.24M5.62M----
Average Shares used to compute Basic EPS8.4M7.2M6.19M6.05M6.24M5.62M----
Income Before Nonrecurring Items-3M1.05M-1.73M-7.15M-2.88M-6.28M----
Income from Nonrecurring Items----------
AIT THERAPEUTIC Earnings Per Share Basic Net
-0.360.15-0.28-1.18-0.46-1.12----
AIT THERAPEUTIC Earnings Per Share Diluted Net
-0.360.14-0.28-1.18-0.46-1.12----
EPS Diluted Before Nonrecurring Items-0.360.14-0.28-1.18-0.46-1.12----
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

It is very helpful to read a report on AIT THERAPEUTIC stock analysis. An investor must check the following items in an income statement:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that AITB stock has a topline or revenue of $- for 2019 Q1 as per this AIT THERAPEUTIC revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. AITB stock had a poor bottom line growth.

The income statement is also called the profit and loss statement. Apart from the AITB income statement, one can check the AIT THERAPEUTIC historical stock prices to check how the price has moved with time.

AIT THERAPEUTIC Income Statement - Key Financial Ratios

Other Income Statements - AIT THERAPEUTIC Industry Peers

AVENUE THERAPTC income statement, Biomerica income statement, ProPhase Labs income statement